Key Highlights

  • ClearOne (NASDAQ:CLRO) fell 3.19% pre-market to a listed USD 3.76 on 936 shares, with a market capitalization of USD 10 million and an RSI of 42.1 labeled Down.
  • On October 8 ClearOne received a Nasdaq staff determination to delist its shares because it did not meet the USD 2.5 million minimum stockholders' equity requirement, and it plans to request a hearing by October 15.
  • Majority holders approved a below-market unit offering of up to USD 15 million on August 25, and the company agreed to merge with Cortigent on July 1.
  • The stock fell 3.19% pre-market on 936 shares, and the USD 15 million raise exceeds the USD 10 million market value.

What Is Moving the Stock

ClearOne disclosed on October 8 that Nasdaq staff determined to delist its securities after it failed to complete the remedial actions in a compliance plan for the stockholders' equity requirement. The company intends to request a hearing before a Nasdaq Hearings Panel by October 15, and a hearing request typically stays suspension while the panel decides. The stock fell 3.19% pre-market to USD 3.76 on only 936 shares, and the market value is about USD 10 million.

The Data Behind the Move

On August 25 majority holders approved the issuance of units of one share and one warrant for up to USD 15 million at a price below the Nasdaq minimum price, and on July 1 the company agreed to merge with Cortigent. The planned USD 15 million unit raise is about 1.5 times the entire USD 10 million market value, simple arithmetic. In March the company sold 437,500 shares at USD 4.00 plus warrants for USD 1.75 million. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 3.88; if it is the last close, the implied pre-market price is near USD 3.64, so check a live quote. Pre-market traded value is only about USD 0.00 million, a tiny slice of the company's size, so few dollars set the price. Volume of 936 shares is very thin, under 1,000 shares, and the screener tag reads Listing notice, which classifies the catalyst and does not set direction.

Risks and What to Watch

Delisting, heavy dilution from a raise larger than the market value and merger execution make the equity highly speculative. What to watch next: the hearing outcome, the unit offering and the Cortigent merger. This is information only and not investment advice. On Wednesday morning the SPY ETF was up about 0.2% and the QQQ ETF was roughly flat, with Bank of America and Morgan Stanley reporting earnings and September CPI data due.

Where Things Stand

Market conditions frame the day: S&P 500 futures were slightly higher, big banks report and CPI is due, while AI hardware stocks stay sensitive to OpenAI revenue worries. ClearOne (NASDAQ:CLRO) is moving with a Nasdaq delisting determination and a large dilutive raise. A pre-market drop on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is the hearing outcome, the unit offering and the Cortigent merger. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.